Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective

Journal of Diabetes Research

Volumn 2017, Issue , 2017, Pages

  Xue, Rui ^a   Gui, Dingkun ^a   Zheng, Liyang ^a   Zhai, Ruonan ^a   Wang, Feng ^a   Wang, Niansong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ASTRAGALOSIDE IV; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCAGON LIKE PEPTIDE 1; HERBACEOUS AGENT; NOTOGINSENOSIDE R1; QIDAN DIHUANG GRAIN; UNCLASSIFIED DRUG; VITAMIN D; YIQI YANGYIN HUOXUE; GLUCOSE BLOOD LEVEL;

CHINA; CHINESE MEDICINE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DYSLIPIDEMIA; END STAGE RENAL DISEASE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INCIDENCE; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PROTEINURIA; REVIEW; STEM CELL TRANSPLANTATION; TRIPTERYGIUM; ANALYSIS; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

BLOOD GLUCOSE; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MEDICINE, CHINESE TRADITIONAL; RENIN-ANGIOTENSIN SYSTEM; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 85016500211     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2017/1839809     Document Type: Review

References (76)

1. B. Chopra and K. K. Sureshkumar, "Co-stimulatory blockade with belatacept in kidney transplantation," Expert Opinion on BiologicalTherapy, vol. 14, no. 5, pp. 563-567, 2014.
2. J. Brenneman, J. Hill, and S. Pullen, "Emerging therapeutics for the treatment of diabetic nephropathy," Bioorganic and Medicinal Chemistry Letters, vol. 26, no. 18, pp. 4394-4402, 2016.
3. R. Saran, Y. Li, B. Robinson et al., "US renal data system 2014 annual data report: epidemiology of kidney disease in the United States," American Journal of Kidney Diseases, vol. 66, no. 1, supplement 1, pp. S1-S305, 2015.
4. P. A. Lopez-Vargas, A. Tong, M. Howell, and J. C. Craig, "Educational interventions for patients with CKD: a systematic review," American Journal of Kidney Diseases, vol. 68, no. 3, pp. 353-370, 2015.
5. K. Uhlig, J. S. Berns, S. Carville et al., "Recommendations for kidney disease guideline updating: a report by the KDIGO Methods Committee," Kidney International, vol. 89, no. 4, pp. 753-760, 2016.
6. I.H.DeBoer, T. C. Rue, Y.N.Hall, P. J.Heagerty,N. S.Weiss, and J. Himmelfarb, "Temporal trends in the prevalence of diabetic kidney disease in theUnited States,"TheJournal of the American Medical Association, vol. 305, no. 24, pp. 2532-2539, 2011.
7. "KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease," American Journal of Kidney Diseases, vol. 49, no. 2, supplement 2, pp. S12-S154, 2007.
8. K. R. Tuttle, G. L. Bakris, R. W. Bilous et al., "Diabetic kidney disease: a report from an ADA consensus conference," Diabetes Care, vol. 37, no. 10, pp. 2864-2883, 2014.
9. J. H. Ahn, J. H. Yu, S.-H. Ko et al., "Prevalence and determinants of diabetic nephropathy in Korea: Korea National Health and Nutrition examination survey," Diabetes and Metabolism Journal, vol. 38, no. 2, pp. 109-119, 2014.
10. A. Irannejad, A. Ghajar, M. Afarideh et al., "Association of peripheral nesfatin-1 with early stage diabetic nephropathy," Pathophysiology, 2016.
11. S. Katayama, D. Yamada, M. Nakayama et al., "A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetesmellitus and diabetic nephropathy," Journal of Diabetes and Its Complications, 2016.
12. M. Fouad, H. Fathy, and A. Zidan, "Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients," Jornal Brasileiro de Nefrologia, vol. 38, no. 4, pp. 403-410, 2016.
13. P. I. Machingura, V. Chikwasha, P. N. Okwanga, and E. Gomo, "Prevalence of and factors associated with nephropathy in diabetic patients attending an outpatient clinic in Harare, Zimbabwe," The American Journal of Tropical Medicine and Hygiene, vol. 96, no. 2, pp. 477-482, 2017.
14. A. Perkowska-Ptasinska, D. Deborska-Materkowska, A. Bartczak et al., "Kidney disease in the elderly: biopsy based data from 14 renal centers in Poland," BMC Nephrology, vol. 17, article 194, 2016.
15. G. Kaidonis, M. C. Gillies, S. Abhary et al., "A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients," Acta Diabetologica, vol. 53, no. 4, pp. 643-650, 2016.
16. P. Li, Y. Chen, J. Liu et al., "Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial," PLoS ONE, vol. 10, no. 5, Article IDe0126027, 2015.
17. American Diabetes Association, "Diagnosis and classification of diabetes mellitus," Diabetes Care, vol. 37, supplement 1, pp. S81-S90, 2013.
18. W. Yang, J. Lu, J.Weng et al., "Prevalence of diabetes among men and women in China," The New England Journal of Medicine, vol. 362, no. 12, pp. 1090-1101, 2010.
19. L.Wang, M. Zhou, T. Astell-Burt et al., "Geographical variation in diabetes prevalence and detection in China:multilevel spatial analysis of 98,058 adults," Diabetes Care, vol. 38, no. 1, pp. 72-81, 2015.
20. L. Zhang, F.Wang, L.Wang et al., "Prevalence of chronic kidney disease in China: a cross-sectional survey," The Lancet, vol. 379, no. 9818, pp. 815-822, 2012.
21. Z. Liu, "Nephrology in China," Nature Reviews Nephrology, vol. 9, no. 9, pp. 523-528, 2013.
22. S. Dagogo-Jack and J. V. Santiago, "Pathophysiology of Type 2 diabetes and modes of action of therapeutic interventions," Archives of Internal Medicine, vol. 157, no. 16, pp. 1802-1817, 1997.
23. S. Dagogo-Jack, "Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management," Journal of the National Medical Association, vol. 95, no. 9, pp. 774-789, 2003.
24. L. S. Stryker, "Modifying risk factors: strategies that work diabetes mellitus," Journal of Arthroplasty, vol. 31, no. 8, pp. 1625-1627, 2016.
25. T. Matsusaka, E. Sandgren, A. Shintani et al., "Podocyte injury damages other podocytes," Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1275-1285, 2011.
26. L. Barisoni and P.Mundel, "Podocyte biology and the emerging understanding of podocyte diseases," American Journal of Nephrology, vol. 23, no. 5, pp. 353-360, 2003.
27. A. Greka and P. Mundel, "Cell biology and pathology of podocytes," Annual Review of Physiology, vol. 74, pp. 299-323, 2012.
28. P. Mundel and J. Reiser, "Proteinuria: an enzymatic disease of the podocyte," Kidney International, vol. 77, no. 7, pp. 571-580, 2010.
29. J. Peti-Peterdi and A. Sipos, "A high-powered view of the filtration barrier," Journal of the American Society of Nephrology, vol. 21, no. 11, pp. 1835-1841, 2010.
30. R. Bressler and D. G. Johnson, "Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus," Archives of Internal Medicine, vol. 157, no. 8, pp. 836-848, 1997.
31. A. L. Harrison, N. Shields, N. F. Taylor, and H. C. Frawley, "Exercise improves glycaemic control inwomen diagnosedwith gestational diabetes mellitus: a systematic review," Journal of Physiotherapy, vol. 62, no. 4, pp. 188-196, 2016.
32. S. G. Schorr, H.-P. Hammes, U. A. Müller, H.-H. Abholz, R. Landgraf, and B. Bertram, "The prevention and treatment of retinal complications in diabetes," Deutsches Ärzteblatt International, vol. 113, no. 48, pp. 816-823, 2016.
33. P. Fioretto, "Renal protection in diabetes: role of glycemic control," Journal of the American Society of Nephrology, vol. 17, no. 4, supplement 2, pp. S86-S89, 2006.
34. F. Ismail-Beigi, T. Craven, M. A. Banerji et al., "Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial," The Lancet, vol. 376, no. 9739, pp. 419-430, 2010.
35. W. Pimenta, M. Korytkowski,W. Evron et al., "Pancreatic betacell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative," JAMA: The Journal of the American Medical Association, vol. 273, no. 23, pp. 1855-1861, 1995.
36. J. Ba, P. Han, G. Yuan et al., "Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin," Journal of Diabetes, 2016.
37. S. E. Inzucchi, D. G. Maggs, G. R. Spollett et al., "Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus," New England Journal of Medicine, vol. 338, no. 13, pp. 867-872, 1998.
38. M. K. Cavaghan, D. A. Ehrmann, M. M. Byrne, and K. S. Polonsky, "Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance,"The Journal of Clinical Investigation, vol. 100, no. 3, pp. 530-537, 1997.
39. W. J. Malaisse and P. Lebrun, "Mechanisms of sulfonylureainduced insulin release," Diabetes Care, vol. 13, supplement 3, pp. 9-17, 1990.
40. T. Y. Nelson, K. L. Gaines,A. S. Rajan, M. Berg, and A. E. Boyd III, "Increased cytosolic calcium. A signal for sulfonylureastimulated insulin release from beta cells," Journal of Biological Chemistry, vol. 262, no. 6, pp. 2608-2612, 1987.
41. O. G. Kolterman, R. S. Gray, G. Shapiro, J. A. Scarlett, J. Griffin, and J.M.Olefsky, "The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects," Diabetes, vol. 33, no. 4, pp. 346-354, 1984.
42. S. Ravindran, V. Kuruvilla, K. Wilbur, and S. Munusamy, "Nephroprotective effects of metformin in diabetic nephropathy," Journal of Cellular Physiology, vol. 232, no. 4, pp. 731-742, 2017.
43. S. Gu, Y. Zeng, D. Yu, X. Hu, H. Dong, and C. Hu, "costeffectiveness of saxagliptin versus acarbose as second-line therapy in type 2 diabetes in China," PLOS ONE, vol. 11, no. 11, p. e0167190, 2016.
44. R. A. DeFronzo and M. Abdul-Ghani, "Type 2 diabetes can be prevented with early pharmacological intervention," Diabetes Care, vol. 34, no. S2, pp. S202-S209, 2011.
45. G. Eknoyan, T. Hostetter, G. L. Bakris et al., "Proteinuria and othermarkers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)," American Journal of Kidney Diseases, vol. 42, no. 4, pp. 617-622, 2003.
46. N. Futrakul and P. Futrakul, "Therapeutic resistance to ACEI and ARB combination in macroalbuminuric diabetic nephropathy," Clinical Nephrology, vol. 78, no. 3, p. 250, 2012.
47. F. Ren, L. Tang, Y. Cai et al., "Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy," Renal Failure, vol. 37, no. 4, pp. 548-561, 2015.
48. A. S. Bomback, A. V. Kshirsagar, M. A. Amamoo, and P. J. Klemmer, "Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review,"American Journal of KidneyDiseases, vol. 51, no. 2, pp. 199-211, 2008.
49. B. Chogtu, R. Magazine, and K. L. Bairy, "Statin use and risk of diabetes mellitus," World Journal of Diabetes, vol. 6, no. 2, pp. 352-357, 2015.
50. C. R. Sirtori, "The pharmacology of statins," Pharmacological Research, vol. 88, pp. 3-11, 2014.
51. B. Chogtu, R.Magazine, and K. L. Bairy, "Response to comment on: statin use and risk of diabetes mellitus," World Journal of Diabetes, vol. 7, no. 18, pp. 481-482, 2016.
52. H. Sternlicht and G. L. Bakris, "Management of hypertension in diabetic nephropathy: how low should we go?" Blood Purification, vol. 41, no. 1-3, pp. 139-143, 2016.
53. G. L. Bakris, M. R. Weir, S. Shanifar et al., "Effects of blood pressure level on progression of diabetic nephropathy: Results from The RENAAL Study," Archives of Internal Medicine, vol. 163, no. 13, pp. 1555-1565, 2003.
54. K. J. Schjoedt, K. Rossing, T. R. Juhl et al., "Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy," Kidney International, vol. 70, no. 3, pp. 536-542, 2006.
55. C. Zhou, F. Lu, K. Cao, D. Xu, D. Goltzman, and D. Miao, "Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1α-hydroxylase knockout mice," Kidney International, vol. 74, no. 2, pp. 170-179, 2008.
56. M. R. Haussler, "Vitamin D receptors: nature and function," Annual Review of Nutrition, vol. 6, pp. 527-562, 1986.
57. W. Yuan, W. Pan, J. Kong et al., "1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter," Journal of Biological Chemistry, vol. 282, no.41, pp.29821-29830, 2007.
58. T. Larsson, U. Nisbeth, Ö. Ljunggren, H. Jüppner, and K. B. Jonsson, "Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers," Kidney International, vol. 64, no. 6, pp. 2272-2279, 2003.
59. C. Fligny, M. Barton, and P.-L. Tharaux, "Endothelin and podocyte injury in chronic kidney disease," Contributions to nephrology, vol. 172, pp. 120-138, 2011.
60. L. L. Baggio and D. J. Drucker, "Biology of incretins: GLP-1 and GIP," Gastroenterology, vol. 132, no. 6, pp. 2131-2157, 2007.
61. M. M. Sousa, S. D. Yan, D. Stern, and M. J. Saraiva, "Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NFkB) activation," Laboratory Investigation, vol. 80, no. 7, pp. 1101-1110, 2000.
62. T. K. Wöbke, B. L. Sorg, and D. Steinhilber, "Vitamin D in inflammatory diseases," Frontiers in Physiology, vol. 5, article 244, 2014.
63. C. G. Liew and P. W. Andrews, "Stem cell therapy to treat diabetes mellitus," Review of Diabetic Studies, vol. 5, no. 4, pp. 203-219, 2008.
64. A. H.Hamza,W. M. Al-Bishri, L. A.Damiati, and H. H.Ahmed, "Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy," Renal Failure, vol. 39, no. 1, pp. 67-76, 2016.
65. A. J. Peired, A. Sisti, and P. Romagnani, "Renal cancer stem cells: characterization and targeted therapies," Stem Cells International, vol. 2016, Article ID 8342625, 12 pages, 2016.
66. B. Baban, J. Y. Liu, S. Payne, W. Abebe, J. C. Yu, and M. S. Mozaffari, "Status of stem cells in diabetic nephropathy: predictive and preventive potentials," EPMA Journal, vol. 7, no. 1, p. 21, 2016.
67. L. J. Hickson, A. Eirin, and L. O. Lerman, "Challenges and opportunities for stem cell therapy in patients with chronic kidney disease," Kidney International, vol. 89, no. 4, pp. 767-778, 2016.
68. M. E. Ezquer, F. E. Ezquer, M. L. Arango-Rodríguez, and P. A. Conget, "MSCtransplantation: a promising therapeutic strategy to manage the onset and progression of diabetic nephropathy," Biological Research, vol. 45, no. 3, pp. 289-296, 2012.
69. J.Wang, H. Huang, P. Liu et al., "Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats," European Journal of Pharmacology, vol. 553, no. 1-3, pp. 297-303, 2006.
70. W. Y. Pei, C. H. Yang, and X. L. Zhang, "Effects and mechanism of Tripterygium wilfordii on chronic glomerulo nephritis," Genetics and Molecular Research, vol. 15, no. 1, Article ID 15017410, 2016.
71. D. Gui, L. Wei, G. Jian, Y. Guo, J. Yang, and N. Wang, "Notoginsenoside R1 ameliorates podocyte adhesion under diabetic condition through α3β1 integrin upregulation in vitro and in vivo," Cellular Physiology and Biochemistry, vol. 34, no. 6, pp. 1849-1862, 2014.
72. Y. Chen, D. Gui, J. Chen, D. He, Y. Luo, and N. Wang, "Downregulation of PERK-ATF4-CHOP pathway by astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats," Cellular Physiology and Biochemistry, vol. 33, no. 6, pp. 1975-1987, 2014.
73. L. Xiang, P. Jiang, L. Zhou et al., "Additive effect of qidan dihuang grain, a traditional chinese medicine, and angiotensin receptor blockers on albuminuria levels in patients with diabetic nephropathy: a randomized, parallel-controlled trial," Evidencebased Complementary and Alternative Medicine, vol. 2016, Article ID 1064924, 8 pages, 2016.
74. J. Y. Ou, D. Huang, Y. S. Wu et al., "A meta-analysis of randomized controlled trials of yiqi yangyin huoxue method in treating diabetic nephropathy," Evidence-Based Complementary andAlternativeMedicine, vol. 2016,Article ID3257603, 12pages, 2016.
75. Z. Rahimi, "The role of renin angiotensin aldosterone system genes in diabetic nephropathy," Canadian Journal of Diabetes, vol. 40, no. 2, pp. 178-183, 2016.
76. C. M. Lawes, S. V. Hoorn, and A. Rodgers, "Global burden of blood-pressure-related disease, 2001," The Lancet, vol. 371, no. 9623, pp. 1513-1518, 2008.